載入中
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
一般交易時段
US$1.55
−US$0.02 · -1.27%
盤中時間採用ET。市場資料可能有所延遲。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日內區間
目前US$1.55
52週區間
目前US$1.55
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
41
合理估值
情緒
58
多空交錯
風險
66
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日內區間
目前US$1.55
52週區間
目前US$1.55
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月26日 | 1:28 | — | — |
股票分割 | 2025年2月24日 | 1:17 | — | — |
股票分割 | 2024年6月18日 | 1:13 | — | — |
股票分割 | 2024年1月30日 | 1:7 | — | — |
股票分割 | 2023年4月24日 | 1:30 | — | — |
已生效 2026年1月26日
1:28
已生效 2025年2月24日
1:17
已生效 2024年6月18日
1:13
已生效 2024年1月30日
1:7
已生效 2023年4月24日
1:30
報告持有此股票曝險的交易所交易基金。
State Street SPDR Dow Jones Global Real Estate ETFRWO105.63萬0.09%11.92億 USD0.50%US$46.665+0.18%
State Street SPDR Dow Jones International Real Estate ETFRWX82.44萬0.34%2.41億 USD0.59%US$25.15+0.40%
State Street SPDR S&P International Small Cap ETFGWX33.87萬0.04%9.15億 USD0.40%US$45.14-0.27%
State Street SPDR Portfolio Europe ETFSPEU6.06萬0.01%6.89億 USD0.07%US$53.155+0.25%
Vanguard Extended Market ETFVXF4.1萬0.00%954億 USD0.05%US$232.1-0.61%State Street SPDR Dow Jones Global Real Estate ETFRWOState Street SPDR Dow Jones International Real Estate ETFRWXState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUVanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
